PolyTouch Medical Ltd., a leading developer of hernia mesh placement technologies today announced that it has appointed William (Bill) Edelman as Chairman.


Mr. Edelman brings over 32 years of experience in various executive positions in the medical device industry, most recently as President & Chief Executive Officer, TYRX, Inc. While with TYRX, Mr. Edelman was responsible for strategic planning, business development and general management. Mr. Edelman led the development, FDA clearance and commercialization in over 6,600 patients of AIGIS, a drug releasing implant which combats infection in pacemaker and implanted defibrillator patients. During his tenure, Mr. Edelman raised $27MM in venture financing, $5.5MM equity financing from Boston Scientific and $7MM in strategic partner payments. Prior to TYRX, Mr. Edelman has held executive level positions at MicroSense International, LLC (bio-sensing), FibraSonics, Inc. (ultrasonic surgical products), NeuroMod, Inc. (neuro-stimulation technologies), St. Jude Medical, Inc. ( STJ), Pfizer, Inc. ( PFE), and Baxter International, Inc. ( BAX). Mr. Edelman graduated with a degree in Biomedical Engineering from Rensselaer Polytechnic Institute. He has been issued 15 U.S. patents and is an applicant on 3 additional pending patent applications.


"William's deep experience in the medical device industry and his outstanding track record of fundraising, product development and commercialization is uniquely suited to PolyTouch Medical. I am delighted to have Bill on our Board; his leadership and experience will lead PolyTouch to further success" remarked Ofek Levin, Founder and CEO for PolyTouch Medical.


Mr. Edelman commented, "I am excited to join PolyTouch Medical Board to support shaping the business development strategy and Management's development efforts. PolyTouch's technology is unique and has the potential to revolutionize hernia repair procedures. I look forward to working with an impressive team focused on development and commercialization of products that address important and unmet clinical needs."